Monthly LHD Call January 10, 2023



Opening Remarks

Opening Remarks	Doug Urland, MPA LHD Operations Liaison
Epi Picture/CDC Mpox Funding	Zack Moore, MD, MPH State Epidemiologist and Epidemiology Section Chief
Flu/COVID-19 and Mpox Vaccine Update	Carrie Blanchard, PharmD, MPH Immunization Branch Interim Director
COVID-19/Mpox Testing and Therapeutics Updates	Tim Davis, PharmD, BCNP, PMP Medical Countermeasures Coordinator
CI/CT Update	Laura Farrell Contact Tracing Program Manager
NCEDSS/COVID Update	Anita Valiani, MPH NC EDSS Epidemiologist and Manager
Question & Answer Session	Open for Questions – Please use the Zoom Q&A function



Epi Picture/CDC Mpox Funding


Opening Remarks	Doug Urland, MPA LHD Operations Liaison
Epi Picture/CDC Mpox Funding	Zack Moore, MD, MPH State Epidemiologist and Epidemiology Section Chief
Flu/COVID-19 and Mpox Vaccine Update	Carrie Blanchard, PharmD, MPH Immunization Branch Interim Director
COVID-19/Mpox Testing and Therapeutics Updates	Tim Davis, PharmD, BCNP, PMP Medical Countermeasures Coordinator
CI/CT Update	Laura Farrell Contact Tracing Program Manager
NCEDSS/COVID Update	Anita Valiani, MPH NC EDSS Epidemiologist and Manager
Question & Answer Session	Open for Questions – Please use the Zoom Q&A function



Flu/COVID-19 and Mpox Vaccine Update

Opening Remarks	Doug Urland, MPA LHD Operations Liaison
Epi Picture/CDC Mpox Funding	Zack Moore, MD, MPH State Epidemiologist and Epidemiology Section Chief
Flu/COVID-19 and Mpox Vaccine Update	Carrie Blanchard, PharmD, MPH Immunization Branch Interim Director
COVID-19/Mpox Testing and Therapeutics Updates	Tim Davis, PharmD, BCNP, PMP Medical Countermeasures Coordinator
CI/CT Update	Laura Farrell Contact Tracing Program Manager
NCEDSS/COVID Update	Anita Valiani, MPH NC EDSS Epidemiologist and Manager
Question & Answer Session	Open for Questions – Please use the Zoom Q&A function





UPCOMING VIRTUAL MEETINGS

- On January 26th, <u>VRBPAC</u> will consider whether and how the composition and schedule for primary doses and boosters should be modified.
- The ACIP is <u>scheduled</u> to meet February 22nd and 23^{rd.}






Following <u>FDA authorization</u>, the <u>CDC has recommended</u> the use of updated (bivalent) COVID-19 vaccines to children aged 6 months through 5 years. Unlike for older age groups, **these products are not eligible for mix-and-match use**.

- Moderna: Children ages 6 months through 5 years who previously completed a Moderna primary series can now receive a Moderna bivalent booster 2 months after their final primary series dose.
- 2. Pfizer: Children ages 6 months through 4 years who are completing a Pfizer primary series will receive a Pfizer bivalent vaccine as their third primary dose. Effective immediately, the third dose of Pfizer (monovalent) is no longer authorized for this age group.

Access the Updated Statewide Standing Orders Here





COVID-19 VACCINE UPTAKE IN NC



Boosters

These data shows COVID-19 booster doses as a percentage of those who finished their initial vaccine. This includes additional doses which can be given to immunocompromised people. Explore the rest of the dashboard here.







VACCINE EXPIRATION DATE EXTENSION AND BEYOND-USE DATES (BUD)



Pfizer-BioNTech COVID-19 Vaccine Expiration Date Extension and Beyond-Use Dates (BUD)

- The FDA has extended the expiration date for Pfizer COVID-19 vaccine (monovalent and bivalent) from 12 to **18 months** from manufacturer date.
 - This expiration date extension applies to both vaccine vials currently stored at ultra-cold temperatures (-90°C and -60°C [- 130°F and -76°F]) and at refrigerated temperatures (2°C and 8°C [36°F and 46°F]).
- Before discarding any vaccine, please check vaccine expiration dates using <u>Pfizer-BioNTech's Expiration Date Checker</u>



Moderna COVID-19 Vaccine Expiration Date Extension and Beyond-Use Dates (BUD)

- The FDA has extended the expiration date for select lots of Moderna COVID-19 vaccine (monovalent). This extension includes some lots of Moderna COVID-19 Vaccine (ages 12+ and 6-11).
 - This expiration date extension applies to both vaccine vials currently stored at both frozen temperatures between (-50°C and -15°C [-58°F and 5°F]) and refrigerated temperatures (2°C and 8°C [36°F and 46°F])
- Before discarding any vaccine, please check vaccine expiration dates using <u>the Moderna</u>
 <u>Vial Expiration Checker.</u>





MERGING OPERATIONS: CVMS TO NCIR TRANSITION

Due to mass vaccination demands during initial roll out of the COVID-19 vaccine, the state utilized the COVID-19 Vaccine Management System (CVMS) as a mass vaccination module to track vaccine supply and administration. Now that COVID-19 vaccines are part of routine care, NCDHHS is beginning to return the routine management of COVID-19 vaccine to the North Carolina Immunization Registry (NCIR).

What's Next?

- The transition to NCIR will be done in stages. Practices who need to transition from CVMS to NCIR are beginning to be contacted by DHHS.
- <u>VFC providers</u> may reference <u>this email</u> for further instructions on how to transition to NCIR.



SAVE THE DATE: VACCINES FOR CHILDREN 2023 TRAINING SESSION

Join us for the 2023 NCDHHS
VFC Virtual Training! This virtual
training will address new
immunization
recommendations and changes
in best practices. Sessions will
repeat on March 28 and April 4.



MARCH 28

8:30am - 12:15pm

APRIL 4

1:00pm - 4:45pm




AGREEMENT ADDENDUM 715 OR 716 FUNDS

- AA 715 supports general immunization services and administration of vaccines
- AA 716 supports COVID-19 vaccine services and administration of COVID-19 vaccines
- Neither allow for the purchase of vaccines



Access the AA715 Allowable Expenditure

Chart



MPOX OFFICE HOURS DISCONTINUED

- Immunization Branch is discontinuing the Mpox office hours.
- You may also refer to the following resources:
 - NCDDHHS Mpox website
 - JYNNEOS FAQ document
 - Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Monkeypox Outbreak



Update to Mpox Vaccination Program Provider Agreement to allow for more flexibility in administration routes

- Previous Guidance: All doses of JYNNEOS must be administered intradermally (unless contraindicated)
- New Guidance: Healthcare providers should decide whether to offer the intradermal or subcutaneous regimen based on balancing optimal vaccination use and acceptance, feasibility of administration, and available vaccine supply.


Access the Mpox Vaccination Program Provider
Agreement Here



COVID-19/Mpox Testing and Therapeutics Updates

Opening Remarks	Doug Urland, MPA LHD Operations Liaison
Epi Picture/CDC Mpox Funding	Zack Moore, MD, MPH State Epidemiologist and Epidemiology Section Chief
Flu/COVID-19 and Mpox Vaccine Update	Carrie Blanchard, PharmD, MPH Immunization Branch Interim Director
COVID-19/Mpox Testing and Therapeutics Updates	Tim Davis, PharmD, BCNP, PMP Medical Countermeasures Coordinator
CI/CT Update	Laura Farrell Contact Tracing Program Manager
NCEDSS/COVID Update	Anita Valiani, MPH NC EDSS Epidemiologist and Manager
Question & Answer Session	Open for Questions – Please use the Zoom Q&A function





COVID-19 Testing/Therapeutics and Oseltamivir Shortage Updates

Tim Davis, PharmD

Medical Countermeasures Coordinator

North Carolina Public Health Preparedness and Response

COVID Testing Updates:

Community Access Points (CAPs)
Vendor Supported COVID-19 Community Testing
Potential Pilot of LTS testandgo Kiosks



Continue to Recruit Community Access Points (CAPs)

- Only three counties remain without a CAP
 - Alexander, Moore, Rutherford
- Becoming a CAP is EASY!
 - For more information:
 - https://covid19.ncdhhs.gov/testing-treatment/information-testing-providers-and-partners#free
 - To order at-home tests kits:
 - https://app.smartsheet.com/b/form/231af981469c452f9a81045c2fee1f2a
 - We have transitioned to a weekly ordering schedule
 - Monday 10 a.m. deadline; shipments occur the following week
- Rapid antigen tests remain effective at detecting the current circulating variants

In Need of Support?

<u>COVID-19 Testing and</u>

<u>Therapeutics Inquiry Intake</u>

<u>Form</u>

Vendor Supported COVID-19 Community Testing

- Vendor supported community testing is currently funded by FEMA
 - FEMA funding expected to end in early 2023
 - Expect at least a 30-day notice from FEMA
- Vendor supported testing will end by 3/31/2023 or sooner
 - Depends on timing of FEMA funding sunset
 - All testing vendor contracts expire on or before 3/31/2023
- Community based organizations have been central to this response
 - Continue to explore new ways of working together

TESTANDGO© SELF-SERVICE KIOSK PILOT

DELIVERS CARE TO PATIENTS THROUGH DECENTRALIZED ACCESS POINTS ACCESSIBLE 24/7/365 WITHIN THE LOCAL COMMUNITY

Services / Tests	NOW COVID-19 PCR Antigen FUTURE Vend: COVID + Flu, STI / HIV, CVD / DM, Naloxone, Fentanyl strips Telemedicine Prescriptions
Value	 No-Cost Testing is free for individuals regardless of insurance status, who are: Symptomatic Exposed Access to Care – Convenience, weather, availability Payors (3rd party) No clinical staff
Requirements	 Outside electrical outlet; cellular connection or WIFI (handled by LTS) ADA compliant area Free parking and access to all persons SVI minimum 0.5 or Higher (Medium-High/HIGH)



Watch testandgo Kiosk Demo



FAQ'S

?	Answers
How long is the ICATT contract good for?	Current POP is until end of May 2023, contract extends until 2025
What is the cost to the state/county/city?	None (if kiosks are placed under ICATT)
Who maintains the kiosk?	LTS provides personnel: re-stock kits; retrieve specimens to send to the lab; and handle any maintenance on the machine. This is a service provided.
What does a site need?	Outside electrical outlet; Kiosk needs cellular connection or WIFI (handled by LTS); ADA compliant area; free parking and access to all persons
What data will the state get?	Data is sent to HHS protect as well as the state for any reportable disease requirements
What happens after the ICATT contract ends?	LTS will work with states to identify other funding streams to cover cost of keeping kiosks in state
Is there a minimum number of tests/week?	15-20/kiosk/week



COVID Therapeutics Updates:


COVID Telemedicine Partnership with StarMed Healthcare



Statewide COVID-19 Telemedicine Platform Launched 12/13

- Partnership with StarMed Healthcare to offer FREE telemedicine screenings
 - www.starmed.care/nc or 704-941-6000
- Available 7 days a week, 9am to 7pm
- No cost passed to patient, regardless of insurance status
 - Personal insurance will be billed, if available
- ID not required to participate
- Website and registration form available in 7 languages
 - Consultations available in more than 200 languages (including ASL)
- Prescriptions sent to pharmacy of choice or mail-ordered overnight
- Time-limited program, estimated to last until mid-March

Initial Telemedicine Program Data



Please help us promote this telemedicine program to your patients!

- English/Spanish Flyer
- Social Media Tool Kit
- Make-A-Plan Flyer *Coming Soon*

Overall Statistics

Total individuals	1870
Uninsured Total	19%
Prescription Success	~90%
Paxlovid	~80%
Lagevrio	~20%

How did they hear about us?

Google/Internet Search	34.4%
Family/Friend	33.4%
DHHS/Health Department Referral	18.1%
StarMed Testing Site	8.3%
Social Medial	3.4%
CAP site	1.5%
On Location	1.0%

Oseltamivir Shortage Situation:

Survey Responses and Extended Tamiflu Supply



Oseltamivir Shortage

- Thank you for completing our survey!
 - 168 Reponses (LHDs and Hospitals)
- Key Hospital Takeaways
 - Oseltamivir generally available on allocation from wholesaler
 - 5 hospitals indicated "immediate need"
 - Upon follow-up these needs were not urgent
- Key LHD takeaways
 - Hearing from providers of difficulty locating oseltamivir for patients
 - No urgent needs
- Major Pharmacy Partners (CVS, Walgreens, WalMart, Ingles, & CPESN)
 - Experiencing intermittent supply issues not uncommon for this time of year
 - Pediatric liquid formulation more difficult to come by, but able to compound

Extended Tamiflu Supply

ASPR Webpage: Improving Access to Influenza Countermeasures for U.S. Jurisdictions

- 29 Locations reported having extended Tamiflu in their local stockpile
 - 23 LHDs and 6 Hospitals
 - 1800+ courses reported total
- ONLY Tamiflu purchased by states during 2009 subsidy program eligible for use right now
 - This is represented by Table #2 at link above
 - 12 Locations reported having lot numbers of "state purchased" product that could be used right now:
 - Lot # U2114 (75mg) 273 courses reported
 - Lot # B1008-01 (30mg) 380 courses reported
- What now?
 - Continue to monitor situation
 - Reach out to <u>phpr.sns@dhhs.nc.gov</u> if experiencing major supply issues and plan to use extended supply
 - If situation worsens, Tamiflu is requestable from SNS

Interim Guidance for Clinicians to Prioritize Antiviral Treatment of Influenza in the Setting of Reduced Availability of Oseltamivir

CI/CT Update


Opening Remarks	Doug Urland, MPA LHD Operations Liaison
Epi Picture/CDC Mpox Funding	Zack Moore, MD, MPH State Epidemiologist and Epidemiology Section Chief
Flu/COVID-19 and Mpox Vaccine Update	Carrie Blanchard, PharmD, MPH Immunization Branch Interim Director
COVID-19/Mpox Testing and Therapeutics Updates	Tim Davis, PharmD, BCNP, PMP Medical Countermeasures Coordinator
CI/CT Update	Laura Farrell Contact Tracing Program Manager
NCEDSS/COVID Update	Anita Valiani, MPH NC EDSS Epidemiologist and Manager
Question & Answer Session	Open for Questions – Please use the Zoom Q&A function



NC DHHS Case Investigation & Contact Tracing

LHD Meeting

January 10, 2023



CCTC CLINICAL PROGRAM UPDATE (SHARED BY EMAIL 11/30/22)

As of March 1, 2023, CCTC staff will no longer administer vaccines or tests for COVID-19 or any other diseases. From now until March, CCTC staff can continue to administer vaccine and tests as needed.

The following AA funds can be alternate sources of support for this work:

- AA 546 Can be used for surveillance, detection, control, and prevention of any communicable diseases, including, but not limited to COVID-19. Please contact Megan Smith at megan.smith1@dhhs.nc.gov with any questions.
- AA715- Can be used to support all immunization services delivery as well as activities that provide immunization education and outreach. For details on allowable expenses, visit the North Carolina Immunization Program (NCIP) Requirements page. Please contact Wendy Holmes at wendy.holmes@dhhs.nc.gov with any questions.
- AA716- Can be used for activities that focus on removing the barriers to accessing COVID-19 vaccine, increasing COVID-19 vaccine confidence, coordinating COVID-19 vaccine services, and expanding its COVID-19 vaccination program. Please contact Haley Shigas at Haley.Shigas@dhhs.nc.gov or Wendy Holmes at wendy.holmes@dhhs.nc.gov with any questions.

Please note that these updates are related to the CCTC Clinical Program only, and have no impact on CCTC CI/CT, data entry, call center or non-clinical vaccine or testing supports.



CI/CT PROGRAM WIND DOWN- LONG TERM GOALS

Over the coming year, as the COVID-19 response and federal funds wind down, we expect to also be winding down the CI/CT Program, including the support of CCTC staff. Here are the goals that we have prepared to guide us through this process.



Shift focus to where COVID-19 outreach can have the biggest impact



Align reductions in CCTC staff with reductions in response expectations



Transition remaining COVID-19 activities at a reasonable and steady pace



Learn from COVID and integrate what we've learned into overall public health response



CI/CT PROGRAM WIND DOWN- UPCOMING CHANGES

Effective 12/19: Guidance changes to focus outreach on linkage to treatment and resources

- Case investigation interviews are no longer recommended
- Outreach guidance prioritizes informational calls to cases patients aged
 65+ and supports connection to new treatment telehealth program
- Transition to this guidance for CCTC staff can start now or happen any time prior to April 1, 2023

April 2023: CCTC staffing model will change to align with updated outreach guidance

- CCTC staff will make phone calls to case patients based on updated outreach guidance only
- CCTC staff management will be centralized and follows guidance strictly (LHD-specific outreach patterns end, staff no longer report to LHD offices)
- All services currently provided by the CCTC Data Entry team are expected to be maintained.



COVID-19 CI/CT GUIDANCE UPDATE- EFFECTIVE 12/19



Shift focus to where COVID-19 outreach can have the biggest impact: linkage to treatment and resources

Current CI/CT Prioritization Guidance	Updated Case Outreach Prioritization Guidance	
Interviews for case patients reported to be linked to a cluster/outbreak or reported as living in a congregate or healthcare setting	Informational calls to case nationts agod 65 L	
Interviews for case patients known to be working or potentially exposed in a high-density setting	Informational calls to case patients aged 65+	
Informational calls to case patients whose CCTO record indicates their text was not delivered	Informational calls to case patients whose CCTO record indicates their text was not delivered	
Informational calls to case patients in populations most likely to have resource needs	Informational calls to case patients in populations most likely to have resource needs based on SVI index	




COVID-19 CI/CT GUIDANCE UPDATE- EFFECTIVE 12/19

Continue to follow outbreak and cluster guidance

- While the CI/CT outreach guidance is changing, outbreak reporting guidance will remain the same and outbreaks/clusters reported to LHDs should continue to be reported to the state.
- Interviewing to identify outbreaks is no longer recommended
- Few outbreak/clusters were being identified by interviews. A small number of outbreaks/clusters may be missed without interviews.
- Guidance is always subject to change and DHHS or LHDs may still recommend interviews in specific cluster/outbreak situations.

New CCTO priority settings functionality can support identification of outbreaks with minimal staff effort. See the job aid on the CD manual to learn more.





CCTC STAFFING UPDATE- APRIL 2023

As of April 2023:

- CCTC staff will be centralized with consistent workflows statewide; staff will make informational calls (no interviews) to case patients as directed by updated outreach guidance only.
- CCTC outreach calls will take place for all counties (opt out only considered where LHD staff are making calls based on the outreach guidance).
- CCTC Data Entry team services are expected to be maintained.
- CCTC staff will continue to support other diseases as directed by DPH (e.g. Ebola/Uganda traveler response) but will not be routinely available for individual LHD-directed support of other diseases.
- CCTC Staff currently working for LHDs on-site will need to shift to remote, centralized work.
 - Requests for on-site non-clinical vaccine support may be considered based on vaccine trends.
 - Any on-site data entry into LHD systems will need to shift to the state Data Entry team.
- We expect to maintain this staffing model through at least August 2023, though it is subject to change based on changes to the overall COVID-19 response.



NCEDSS/COVID Update

Opening Remarks	Doug Urland, MPA LHD Operations Liaison
Epi Picture/CDC Mpox Funding	Zack Moore, MD, MPH State Epidemiologist and Epidemiology Section Chief
Flu/COVID-19 and Mpox Vaccine Update	Carrie Blanchard, PharmD, MPH Immunization Branch Interim Director
COVID-19/Mpox Testing and Therapeutics Updates	Tim Davis, PharmD, BCNP, PMP Medical Countermeasures Coordinator
CI/CT Update	Laura Farrell Contact Tracing Program Manager
NCEDSS/COVID Update	Anita Valiani, MPH NC EDSS Epidemiologist and Manager
Question & Answer Session	Open for Questions – Please use the Zoom Q&A function

NCEDSS/NC COVID UPDATES

- We will be taking NCEDSS offline on Wednesday at 5pm EST for about 4-5 hours to upload babesiosis as a new disease to be available in NCEDSS. Please ensure you have saved all work and logged out by this time.
- There will be a short presentation on Babesisosis presented during an upcoming NCEDSS/NC COVID office hours. Watch for an email on this
- We are also adding AFM and Varicella to the LHD view for vaccine preventable diseases.
- The software we use for our NC COVID and NCEDSS applications is due for an update from the vendor. We have started the process to begin upgrading NC COVID with NCEDSS coming later. Please look out for trainings and system update messages coming your way. Every user will need to sit through a training to gain access to the new version which will have a different look and feel than the current version of NC COVID/NCEDSS.
- As a reminder we have a webinar scheduled on Thursday at 1pm on *Linking to an Outbreak* and office hours scheduled every Tuesday at 10am



Question & Answer Session

Opening Remarks	Doug Urland, MPA LHD Operations Liaison
Epi Picture/CDC Mpox Funding	Zack Moore, MD, MPH State Epidemiologist and Epidemiology Section Chief
Flu/COVID-19 and Mpox Vaccine Update	Carrie Blanchard, PharmD, MPH Immunization Branch Interim Director
COVID-19/Mpox Testing and Therapeutics Updates	Tim Davis, PharmD, BCNP, PMP Medical Countermeasures Coordinator
CI/CT Update	Laura Farrell Contact Tracing Program Manager
NCEDSS/COVID Update	Anita Valiani, MPH NC EDSS Epidemiologist and Manager
Question & Answer Session	Open for Questions – Please use the Zoom Q&A function



Q&A

